Filing Details

Accession Number:
0000899243-21-011086
Form Type:
4
Zero Holdings:
No
Publication Time:
2021-03-10 21:30:11
Reporting Period:
2021-03-09
Accepted Time:
2021-03-10 21:30:11
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1576263 Mirati Therapeutics Inc. MRTX () 1231
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1015747 Joseph Lewis Cay House, Ep Taylor Drive
Lyford Cay
New Providence C5 N7776
No No Yes No
1642355 Ltd. Braslyn Cay House, Ep Taylor Drive
Lyford Cay, New Providence C5 N7776
No No Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2021-03-09 1,107 $195.82 3,134,859 No 4 S Direct
Common Stock Disposition 2021-03-09 4,633 $197.30 3,130,226 No 4 S Direct
Common Stock Disposition 2021-03-09 3,993 $197.81 3,126,233 No 4 S Direct
Common Stock Disposition 2021-03-09 2,237 $199.08 3,123,996 No 4 S Direct
Common Stock Acquisiton 2021-03-09 11,971 $0.00 3,135,967 No 4 M Direct
Common Stock Disposition 2021-03-09 1 $191.00 3,135,966 No 4 S Direct
Common Stock Disposition 2021-03-10 189 $195.52 3,135,777 No 4 S Direct
Common Stock Disposition 2021-03-10 20 $196.12 3,135,757 No 4 S Direct
Common Stock Disposition 2021-03-10 200 $198.00 3,135,557 No 4 S Direct
Common Stock Acquisiton 2021-03-10 410 $0.00 3,135,967 No 4 M Direct
Common Stock Disposition 2021-03-10 1 $195.90 3,135,966 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 M Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Warrant (right to purchase) Disposition 2020-03-09 11,971 $5.60 11,971 $0.00
Common Stock Warrant (right to purchase) Disposition 2020-03-10 410 $5.60 410 $0.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
3,578,450 2017-01-06 No 4 M Direct
3,578,040 2017-01-06 No 4 M Direct
Footnotes
  1. Tese securities are owned directly by Braslyn Ltd ("Braslyn"), which may be deemed to be a member of a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, consisting of (i) Braslyn, (ii) Boxer Capital, LLC, (iii) Boxer Asset Management Inc., (iv) MVA Investors, LLC, (v) Lockend Five, LLC, (vi) Joe Lewis, (vii) Ivan M. Lieberburg, (viii) Aaron I. Davis, (ix) Shehan B. Dissanayake, and (x) Christopher Fuglesang (collectively, the "Boxer Group). Each of Messrs. Fuglesang, Lieberburg, Dissanayake and Davis is a member of Boxer Capital. Each member of the Boxer Group other than Braslyn disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein.
  2. Reflects the weighted average sale price. The reporting person effected multiple same-way open market sale transactions on the same day at different prices through a trade order executed by a broker dealer. The reporting person reported on a single line all such transactions that occurred within a one dollar price range. The reporting person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares sold at each separate price. The range of prices for such transaction is $195.24 to $196.20.
  3. Reflects the weighted average sale price. The reporting person effected multiple same-way open market sale transactions on the same day at different prices through a trade order executed by a broker dealer. The reporting person reported on a single line all such transactions that occurred within a one dollar price range. The reporting person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares sold at each separate price. The range of prices for such transaction is $196.55 to $197.53.
  4. Reflects the weighted average sale price. The reporting person effected multiple same-way open market sale transactions on the same day at different prices through a trade order executed by a broker dealer. The reporting person reported on a single line all such transactions that occurred within a one dollar price range. The reporting person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares sold at each separate price. The range of prices for such transaction is $197.56 to $198.23.
  5. Reflects the weighted average sale price. The reporting person effected multiple same-way open market sale transactions on the same day at different prices through a trade order executed by a broker dealer. The reporting person reported on a single line all such transactions that occurred within a one dollar price range. The reporting person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares sold at each separate price. The range of prices for such transaction is $198.62 to $199.46.
  6. Reflects the weighted average sale price. The reporting person effected multiple same-way open market sale transactions on the same day at different prices through a trade order executed by a broker dealer. The reporting person reported on a single line all such transactions that occurred within a one dollar price range. The reporting person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares sold at each separate price. The range of prices for such transaction is $195.11 to $196.09.
  7. The warrants do not have an expiration date and are not exercisable to the extent that, following exercise of such warrants, the warrant holder and its affiliates would beneficially own more than 19.99% of the issuer's common stock.